Alpha DNA Investment Management’s iShares Russell 2000 ETF IWM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$21.6K Buy
+100
New +$20.1K 0.24% 13
2024
Q3
Sell
-601
Closed -$129K 221
2024
Q2
$122K Hold
601
0.05% 202
2024
Q1
$126K Buy
601
+600
+60,000% +$120K 0.05% 192
2023
Q4
$201 Hold
1
﹤0.01% 183
2023
Q3
$177 Hold
1
﹤0.01% 169
2023
Q2
$187 Hold
1
﹤0.01% 147
2023
Q1
$178 Hold
1
﹤0.01% 147
2022
Q4
$174 Buy
+1
New +$178 ﹤0.01% 149
2022
Q2
Sell
-17,941
Closed -$3.31M 143
2022
Q1
$1.17M Buy
+17,941
New +$3.66M 0.82% 81
2021
Q2
Sell
-231,200
Closed -$52M 364
2021
Q1
$1.87M Buy
231,200
+227,701
+6,508% +$49.7M 2.15% 3
2020
Q4
$1.65M Buy
+3,499
New +$612K 1.75% 2

Other funds holding IWM

Alpha DNA Investment Management's IWM Position: Q2 2025 in Review

Alpha DNA Investment Management opened a new position in iShares Russell 2000 ETF (IWM) in Q2 2025: 100 shares worth $21.6K. The stake represents 0.24% of the portfolio and ranks #13 among its holdings. This is a return to the name: Alpha DNA Investment Management previously reported a position in IWM as recently as Q2 2024.

Alpha DNA Investment Management first reported a position in IWM in Q4 2020 and has held it in 11 quarters since. The position peaked at $1.87M in Q1 2021. 2,362 funds tracked by Wall St. Rank hold IWM as of Q2 2025.

  • Alpha DNA Investment Management held 100 shares of iShares Russell 2000 ETF worth $21.6K as of Q2 2025.
  • iShares Russell 2000 ETF was a new Alpha DNA Investment Management position in Q2 2025.
  • iShares Russell 2000 ETF made up 0.24% of Alpha DNA Investment Management's portfolio in Q2 2025, its #13 holding.
  • Alpha DNA Investment Management first reported a position in iShares Russell 2000 ETF in Q4 2020 and has held it in 11 quarters since.
  • Alpha DNA Investment Management's iShares Russell 2000 ETF position peaked at $1.87M in Q1 2021.
  • 2,362 funds tracked by Wall St. Rank held iShares Russell 2000 ETF as of Q2 2025.

Based on Alpha DNA Investment Management's 13F filing for Q2 2025, filed 14 Aug 2025.